Eri Arikawa-Hirasawa Selected Research

perlecan

1/2022	Impact of the heparan sulfate proteoglycan perlecan on human disease and health.
12/2021	Increased Risk of Aortic Dissection with Perlecan Deficiency.
11/2020	Perlecan Facilitates Neuronal Nitric Oxide Synthase Delocalization in Denervation-Induced Muscle Atrophy.
10/2019	Perlecan regulates pericyte dynamics in the maintenance and repair of the blood-brain barrier.
1/2018	Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle.
1/2017	Perlecan is required for the chondrogenic differentiation of synovial mesenchymal cells through regulation of Sox9 gene expression.
8/2015	A missense mutation in domain III in HSPG2 in Schwartz-Jampel syndrome compromises secretion of perlecan into the extracellular space.
4/2013	Synovial perlecan is required for osteophyte formation in knee osteoarthritis.
7/2010	Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition.
4/2010	Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eri Arikawa-Hirasawa Research Topics

Disease

3	Knee Osteoarthritis 01/2017 - 06/2011
2	Dyssegmental dysplasia 01/2022 - 05/2002
2	Muscular Atrophy (Muscle Atrophy) 11/2020 - 04/2014
2	Atrophy 11/2020 - 04/2014
2	Osteophyte 01/2017 - 04/2013
2	Osteochondrodysplasias (Spondyloepiphyseal Dysplasia) 08/2015 - 05/2002
2	Myotonic Disorders (Paramyotonia Congenita) 04/2012 - 05/2002
1	Aortic Dissection 12/2021
1	Glioblastoma (Glioblastoma Multiforme) 10/2019
1	Neoplasms (Cancer) 10/2019
1	Ischemic Stroke 10/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2019
1	Infarction (Infarctions) 10/2019
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2019
1	Corneal Neovascularization 12/2018
1	Hirschsprung Disease (Hirschsprung's Disease) 02/2018
1	Fatty Liver 01/2018
1	Obesity 01/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018
1	Pathologic Neovascularization 03/2016
1	Muscular Diseases (Myopathy) 10/2015
1	Myotonia 08/2015
1	Potassium aggravated myotonia 04/2012
1	Hyperkalemic Periodic Paralysis 04/2012
1	Experimental Sarcoma 07/2010
1	Hypertrophy 07/2010
1	Schizophrenia (Dementia Praecox) 04/2010
1	Tardive Dyskinesia 04/2010
1	Muscular Dystrophies (Muscular Dystrophy) 07/2008
1	Atherosclerosis 10/2004

Drug/Important Bio-Agent (IBA)

12	perlecanIBA 01/2022 - 05/2002
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2018
3	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 10/2019 - 10/2004
2	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2020 - 04/2014
2	UbiquitinIBA 11/2020 - 04/2014
2	Laminin (Merosin)IBA 07/2010 - 07/2008
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 11/2020
1	fibulinIBA 10/2019
1	Angiopoietin-1IBA 10/2019
1	Biological ProductsIBA 10/2019
1	IntegrinsIBA 10/2019
1	Endothelin Receptors (Endothelin Receptor)IBA 02/2018
1	laminin AIBA 02/2018
1	LipidsIBA 01/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	Muscle Proteins (Muscle Protein)IBA 10/2015
1	Sodium Channels (Sodium Channel)IBA 04/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2011
1	MyostatinIBA 07/2010
1	Antipsychotic Agents (Antipsychotics)IBA 04/2010
1	Dopamine AntagonistsIBA 04/2010
1	P-2 (P 2)IBA 04/2010
1	Lipoproteins (Lipoprotein)IBA 10/2004
1	LDL Receptors (LDL Receptor)IBA 10/2004
1	Apolipoproteins E (ApoE)IBA 10/2004
1	ApolipoproteinsIBA 10/2004

Therapy/Procedure

2	Denervation 11/2020 - 04/2014
2	Therapeutics 03/2016 - 04/2013